Top 10 Life Science VC Funds in Italy
A list of 10 VC funds that invest in Life science startups based in Italy. We rank investors based on the number of investments they made in Life science companies from Italy. We update this investor list every month.Top 10 Life Science VC Funds in Italy
Investor | Life Science Italy investments |
---|---|
Sofinnova Partners | 4 |
Indaco Venture Partners | 2 |
Principia SGR | 2 |
Invitalia Ventures | 1 |
JDRF T1D Fund | 1 |
Claris Ventures | 1 |
Roche Venture Fund | 1 |
Italian Angels for Growth | 1 |
Club degli Investitori | 1 |
AbbVie Biotech Ventures | 1 |
Sofinnova Partners is a leading European venture capital firm in life sciences, specializing in healthcare and sustainability. Based in Paris, London and Milan, the firm brings together a team of professionals from all over the world with strong scientific, medical and business expertise.
Show more
Investment focus
- Biotechnology, Health Care, Medical
- Series A, Series B, Series C
- France, United States, United Kingdom
Portfolio highlights
- Cure51 — Cure51 mission is to create a database of cancer survivors to leverage their exceptional biological features and find new drugs to cure Cancer.
- Bioptimus — Our mission is to build the first universal AI foundation model for biology to fuel breakthrough discoveries and accelerate innovations in biomedicine and beyond.
- MISSION Therapeutics — Deubiquitylating enzymes: multiple drug opportunities across therapeutic areas
VENTURE We invest across all sectors with specific focus on technology and digital The largest independent more About Us Portfolio [...]
Show more
Investment focus
- Biotechnology, Health Care, Medical
- Series A, Series B, Funding Round
- Italy, United States, United Kingdom
Portfolio highlights
- Nouscom — Nouscom is a next-generation immunotherapy company developing genetic cancer vaccines and oncolytic viruses..
- Easy Rain — We are Easyrain. Continuous innovation runs in our blood.With our expertise, we develop, simulate, and test solutions, launching our ideas into production. We exploit the basic laws of physics to engineer a tangible solution!
- Alia Therapeutics — Alia Therapeutics is developing next-generation gene-editing medicines to cure rare genetic diseases.
Principia is an Italian Venture Capital firm with over Eur 80M under management. Currently Principia has two funds investing in digital start ups and expansion capital opportunities and in particular cases, we invest also in seed opportunities.
Show more
Investment focus
- Health Care, Biotechnology, Software
- Funding Round, Series A, Seed
- Italy, United States, United Kingdom
Portfolio highlights
- KLISBio — KLISBio is a medtech company currently developing a variety of regenerative medicine implantable products leveraging the power of silk fibroin to promote an endogenous repair of human soft tissues.
- ENTEROME — We are a clinical stage biopharmaceutical company developing novel drugs to transform human health based on our unique ability to de-code molecular interactions in the gut microbiome.
- WISE — WISE (Wiringless Implantable Stretchable Electronics) is a start-up company created in 2011 with the mission of producing the new generation of leads for neuromodulation for treatment of chronic pain and Parkinson: unbreakable, less invasive and cheaper.
Invitalia Ventures SGR manages the “Italia Venture Fund I”, a 87€/Ml sized co-investment fund that invests in early stage operations in Italy. They co-invest up to a maximum of 70% in round A (€ 0.5ML - € 1.5ML) in high growth sectors. Invitalia Ventures, with its network of co-investors not only provides risk capital, but also know-how and anetwork for business development. Main LPs includes the Ministery of Economic Development, the European Investment Bank, Cisco Group, the Sardinian Banking Foundation and Metec Group.They are looking for visionary entrepreneurs who share their passion for innovation.
Growth is their mission!!For more information please contact us at info@invitaliaventures.it or visit our website: www.invitaliaventures.it
Show more
Investment focus
- Software, Medical, Health Care
- Series A, Funding Round, Seed
- Italy, United States, United Kingdom
Portfolio highlights
- Ecomate — The ESG Rating platform for every company
- BigProfiles — A deep understanding of customers let a company tailor marketing campaigns and CRM strategies, but companies have only basic data about customers (e.g. gender or age). External data sources like Social Networks, Public Registries and Socio-Demographic data contain rich information about billions of people, like job titles, levels of education,interests and habits.BigProfiles is a Customer Intelligence SAAS that leverages external information about persons to enrich customer profiling: it can profile a company's customers with previously unknown information about them. Thanks to its Identity Resolution algorithm (the result of a PHD), it identifies a person’s information scattered among external sources.Through this technology, BigProfiles provides customer base analytics and behavior predictions: using Artificial Intelligence on enriched profiles allows to predict churn, fraud and willingness to buy.
- Codemotion — Codemotion is the ecosystem devoted to innovation, focused on developers and coding, open to all programming languages and technologies. Pioneering spirits, it scout the future to deliver a first class experience to our people. Codemotion is one of the biggest tech-conferences in Europe, with an international network of 30.000 developers and 350speakers coming from all over the world and from the most important IT realities.Codemotion draw in its main conferences, thousands of attendees eager to discuss about hottest topics: it tailor for them disruptive proposals ranging from mobile to UX, develops, cloud, big data, gamedev, security, methods, languages, web, Internet of things. Codemotion is also a startup, providing a bunch of services and activities, for personal and business customers.
The JDRF T1D Fund (www.t1dfund.org) is a venture philanthropy fund exclusively devoted to finding and funding the best early-stage T1D commercial opportunities to accelerate the delivery of treatments, preventions, and cures to patients. It was created to solve a critical funding gap in the T1D drug and device development pipeline. Throughpartnerships with private capital, including venture capital, pharma and foundations, the T1D Fund anticipates that it will be able to attract substantially more private investment to the T1D field than occurs today. The T1D Fund will initially focus on artificial pancreas systems, metabolic control, beta cell replacement, prevention, and beta cell restoration therapies, with an exclusive priority on the best commercial opportunities. The T1D Fund will reinvest any realized gains into new investments to further its mission.
Show more
Investment focus
- Biotechnology, Health Care, Therapeutics
- Series A, Series B, Funding Round
- United States, Italy, Canada
Portfolio highlights
- DiogenX — We incorporated DiogenX with the objective to provide new therapeutic solutions for diabetic patients. With Patrick Collombat and the team, we are focused on developing a first-in-class regenerative treatment for type 1 diabetes. Benjamin Charles CEO See the team News See more Our Work OUR APPROACH ABOUT DIABETES
- SAB Biotherapeutics — A biopharmaceutical development company leading the science and manufacturing of antibody therapeutics. Utilizing some of the most advanced antibody science in the world, SAB is delivering the world’s first large-scale platform to create immunoglobulins. This natural production platform holds the potential for treatment of public health problems,rare conditions, long-term diseases and global pandemic threats.
- Veralox Therapeutics — Veralox Therapeutics develops small molecule therapeutics that treat the underlying pathologies of thrombosis and type one diabetes. Based on an understanding of the molecular mechanisms of these diseases, these efforts will lead to new treatment paradigms and better outcomes for patients.
Claris Ventures is a venture capital firm supporting the best scientists in building successful life sciences companies that will impact people's lives
Show more
Investment focus
- Biotechnology, Health Care, Medical
- Seed, Series A, Series B
- Italy, United Kingdom
Portfolio highlights
- NeoPhore — NeoPhore targets the dynamics of cancer neoantigen evolution and makes effective medicines that will become a key part of the next-generation of cancer immunotherapies.
- ALKemist Bio — ALKemist Bio provides cell treatment to cancer patients.
- Repron Therapeutics — Repron Therapeutics provides treatments for solid tumor cases where radical excision is not possible and metastasis or recurrence is extremely likely.
The Roche Venture Fund is the name given to the corporate venture fund of the healthcare company Roche. Roche has allocated CHF 500 million to invest in and develop commercially successful innovative life science companies. Roche has been investing in early stage companies as part of collaborations since the early-1990s and independent ofcollaborations since 2002. All equity investments made by Roche in biotech and diagnostics companies (including collaboration investments) are negotiated and managed by the Roche Venture Fund. In the past 20 years, the Roche Venture Fund has invested in over 60 companies globally. Currently, Roche Venture Fund has a portfolio of around 30 companies located in 10 countries across Europe, North America and the Pacific Region. The fund is an evergreen fund with CHF 500 million available of which approximately 40% is currently invested.The Roche Venture Fund is a committed long-term stable investor with sufficient money reserved in their fund for follow-on financing rounds. As part of a multinational healthcare company, the Roche Venture Fund has access to considerable expertise both internally and externally. We co-invest with leading venture funds, including other corporate venture funds, on a regular basis.
Show more
Investment focus
- Biotechnology, Health Care, Therapeutics
- Series B, Series A, Series C
- United States, United Kingdom, Spain
Portfolio highlights
- DiogenX — We incorporated DiogenX with the objective to provide new therapeutic solutions for diabetic patients. With Patrick Collombat and the team, we are focused on developing a first-in-class regenerative treatment for type 1 diabetes. Benjamin Charles CEO See the team News See more Our Work OUR APPROACH ABOUT DIABETES
- Mironid — Google Analytics is a web analysis service provided by Google. Google utilizes the data collected to track and examine the use of www.mironid.com, to prepare reports on its activities and share them with other Google services. Google may use the data collected to contextualize and personalize the ads of its own advertising network.
- Bonum Therapeutics — Bonum Therapeutics is focused on a proven technology that utilizes allosteric regulation to create targeted, highly active, and less toxic medicines.
IAG is an angel investor network that offers access to its affiliates to early-stage venture opportunities. Its members to date have deployed over 22 million Euros to support 41 startups in the series seed/series A stage in many verticals, among which: Medtech, SAAS, e-commerce, Fintech, and high tech at large. Every investment opportunityat IAG is vetted by a professional team together with expert members of the group. Once invested, the company receives the support of up to two Investment champions, who bring their expertise to the table and help them succeed.
Show more
Investment focus
- Software, E-Commerce, Health Care
- Seed, Angel, Series A
- Italy, United States, United Kingdom
Portfolio highlights
- ALKemist Bio — ALKemist Bio provides cell treatment to cancer patients.
- Viceversa — Viceversa provides capital to European digital businesses to support companies in sustainable and ethical growth. The company was founded in 2021 and has locations in Milan and Dublin.
- Clearbox AI — Benefit from Synthetic Data to unlock your AI projects, overcome privacy issues and improve the utility of your data.
Club degli Investitori (Investors Club) is a network of investors and business angels that invest on early-stage SMEs and startups. The community of 300+ Members (entrepreneurs, CEOs, executive managers) actively scouts for investing opportunities on SMEs & startups and invests with a minimum ticket of €200k. The Club supports business byinvesting capital and by leveraging the Members' network and experience.Club degli Investitori is supported by Unicredit and KPMG Italy.
Show more
Investment focus
- E-Commerce, Health Care, Software
- Seed, Series A, Funding Round
- Italy, United Kingdom, Israel
Portfolio highlights
- Algor Education — Algor Lab is a company that provides tools and materials needed for teaching through artificial intelligence.
- CarpeCarbon — CarpeCarbon is a company that develops technologies for Direct Air Capture (DAC) to extract CO2 directly from the atmosphere. Based in Italy, with a Global vision, the company is made of young researchers (Physics, Chemistry, Astrophysics, Biology, Complex Systems, Engineering) and economists.
- ALKemist Bio — ALKemist Bio provides cell treatment to cancer patients.
AbbVie is a global, research-based biopharmaceutical company formed in 2013 following separation from Abbott Laboratories. The company's mission is to use its expertise, dedicated people and unique approach to innovation to develop and market advanced therapies that address some of the world's most complex and serious diseases. Togetherwith its wholly-owned subsidiary, Pharmacyclics, AbbVie employs ~29,000 people worldwide and markets medicines in more than 175 countries.
Show more
Investment focus
- Biotechnology, Health Care, Therapeutics
- Series A, Series B, Series C
- United States, China, Italy
Portfolio highlights
- Mozart Therapeutics — The company intended to focus on developing novel immune engagers.
- Quanta Therapeutics — Quanta is a biotechnology company uncovering novel cancer therapeutic candidates using allosteric modulation to target driver oncogenes. The company was founded in 2018 and is based in San Francisco, CA.
- DISCO Pharmaceuticals — DISCO Pharmaceuticals is a firm that specializes in large-scale surfaceome unlocking of cancer cells.
Investors by industry
Health Care
Biotech
Community
Marketplace
FinTech
Impact
Proptech
Media (entertainment)
EdTech
Consumer
Climate
Sustainability
Agriculture (agtech)
Venture Capital
Restaurants
Publishing
Beauty
Oil and Gas
Web3
Video Games
Food and Beverage
Clean Energy
Real Estate
Infrastructure
Big Data
Organic Food
Photography
Fashion
Education
B2B
Renewable Energy
Payments
Financial Services
Sporting Goods
Finance
Retail
Medical
Email
Wellness
Social Media
Music
Franchise
Celebrity
Android
Internet
Legal
Google
eSports
Construction
Local
Mobile
Enterprise Software
Sports
Social Network
Manufacturing
Digital Media
Facebook
Art
Social Impact
Recruiting
Platforms
Travel
Fitness
Mobile Advertising
Cannabis
Biotechnology
Hospitality
Automotive
Crowdfunding
Wine And Spirits
Medical Device
Social
CleanTech
Transportation
Mobile Apps
InsurTech
Enterprise
LGBT
Energy
Hardware
Gaming
Artificial intelligence
SaaS
Film
Life Science
Theatre
Non Profit
Software
Cryptocurrency
Blockchain
Investors by country
Canada
United Kingdom
Ireland
Germany
South Korea
Australia
United States
India
New Zealand
Oceania
Armenia
China
Europe
Indonesia
LATAM
Middle East
Spain
Asia
Japan
South Africa
Qatar
Vietnam
Saudi Arabia
Singapore
Sri Lanka
Brazil
Czech Republic
Bahrain
Belize
Africa
Bermuda
Costa Rica
Belarus
Kuwait
Bulgaria
Denmark
Algeria
Georgia
Israel
Gibraltar
Cameroon
Chile
Jersey
Finland
Kazakhstan
Estonia
Faroe Islands
Nicaragua
Greece
Ethiopia
Ghana
Hungary
Croatia
Philippines
Egypt
Belgium
Barbados
Ecuador
France
Italy
Hong Kong
Seychelles
Mali
Lithuania
Slovenia
Cambodia
Liechtenstein
Russian Federation
Kenya
Liberia
Rwanda
Lebanon
Serbia
Mauritius
Uzbekistan
Togo
Morocco
Taiwan
Ukraine
Malaysia
Sierra Leone
Turkey
Tunisia
Norway
Peru
Thailand
Tajikistan
Poland
Myanmar
Uganda
Zimbabwe
Tanzania
San Marino
Cayman Islands
Uruguay
Venezuela
Zambia
Senegal
Puerto Rico
Portugal
Panama
Sweden
El Salvador
Malta
Mexico
Nigeria
United Arab Emirates
Bahamas
Azerbaijan
Iraq
Iceland
Namibia
Luxembourg
Honduras
Isle of Man
Bolivia
Pakistan
Albania
Austria
Argentina
Bangladesh
Grenada
Jordan
Romania
Colombia
Cyprus
Latvia
Oman
Switzerland
Guatemala
Marshall Islands
VC Funds in Italy by industry
Food and Beverage
Restaurants
Media (entertainment)
Venture Capital
Transportation
Financial Services
Cryptocurrency
Big Data
Education
Finance
Payments
Wine And Spirits
Organic Food
Medical
Medical Device
Wellness
Agriculture (agtech)
Internet
Social Media
Digital Media
Manufacturing
Social Network
Art
Android
Mobile
Music
Local
Blockchain
Construction
Software
Sports
Enterprise Software
Travel
CleanTech
Automotive
Hospitality
InsurTech
Recruiting
Platforms
FinTech
Biotechnology
Enterprise
Health Care
Consumer
Biotech
Energy
EdTech
Sustainability
Climate
Impact
Proptech
SaaS
Marketplace
Hardware
Community
Artificial intelligence
Gaming
Mobile Apps
Social
Fashion
Retail
Beauty
B2B
Web3
Life Science
Real Estate
Publishing
Social Impact
Fitness
Oil and Gas
Renewable Energy